Heated market for dueling blood cancer drugs lands BeiGene in court
The Chinese drug maker was sued by U.S. rival AbbVie over alleged patent infringement involving a key product for both companies Key Takeaways: A unit of AbbVie has sued BeiGene…
BGNE.US
6160.HK
Recent Articles
RELATED ARTICLES
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
Discover hidden China stock gems in our weekly newsletter